Company profile
C4 Therapeutics, Inc.
NASDAQ: CCCC · Healthcare · Biotechnology
#480 of 1,422 Healthcare companies by revenue44th-percentile growth
EA Score
49DFH 51DQ 44GM 50SS 55
v0.1 · 65/100 weight · provisional
↑ market scale, balance-sheet leverage · ↓ disclosure history, listing tenure
Methodology →Revenue TTM
$35.0M
Rev growth YoY (TTM)
+2.3%
Net income (FY)
-$105.0M
Employees
104
as of 2026-08-12
Market cap
$427.9M
as of 2026-08-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$35.9M$35.9M2025
Net income-$105.0M-$105.0M2025
Operating income-$115.2M-$115.2M2025
Total assets$359.1M$359.1M2025
Liabilities$102.5M$102.5M2025
Equity$256.6M$256.6M2025
Revenue trend
FY2022 – FY2025 · USD
FY22
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is C4 Therapeutics, Inc.’s revenue?
C4 Therapeutics, Inc. booked $35.9M in FY2025 revenue, growing 1.0% year over year — about the middle of the pack among Healthcare companies we track, at a -292.1% net margin.
Peers · Healthcare
Cytosorbents Corporation55CClearPoint Neuro, Inc.62CSunshine Biopharma, Inc.50DEarth Science Tech, Inc.69BVerrica Pharmaceuticals Inc.51DLeef Brands Inc.57CNeighbors
Middlesex →Key facts
CEOAndrew J. Hirsch
SectorHealthcare
IndustryBiotechnology
HeadquartersWatertown, MA
ExchangeNASDAQ: CCCC
Employees104
IPO date2020-10-02
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.